Global Cancer Cachexia Market Size Projected to Reach $3.21 Billion During the Forecast Period

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Cancer Cachexia Market Expected To Expand Between 2025 And 2029?

The cancer cachexia market size has shown robust growth over recent years. The market is anticipated to increase from $2.47 billion in 2024 to $2.6 billion in 2025, achieving a compound annual growth rate (CAGR) of 5.3%. The historical market expansion is attributable to several factors, including enhanced comprehension of cancer biology, the widespread incidence of cancer, a growing elderly population, an increased emphasis on patient-focused care, a wider array of treatment options, and escalating awareness among healthcare professionals.

The cancer cachexia market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $3.21 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.5%. This anticipated growth during the forecast period is fueled by several factors, including heightened awareness regarding cachexia management, an increase in the elderly population, the increasing integration of innovative therapeutic methods, a rise in healthcare spending, and supportive governmental policies. Prominent developments expected within this period encompass intensified research and development activities, a broader array of treatment choices, enhanced diagnostic accuracy, the implementation of new treatment approaches, and progress in supportive care strategies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp

Which Drivers Are Supporting Growth Of The Cancer Cachexia Market?

The expanding occurrence of cancer is anticipated to fuel the expansion of the cancer cachexia market in the coming period. Cancer is defined as a disease characterized by the uninhibited multiplication of abnormal cells within the body, leading to tumor formation and interference with regular physiological functions. The rise in cancer cases stems from multiple contributing elements, such as shifts in lifestyle, environmental influences, an aging demographic, inherited susceptibility, enhanced diagnostic techniques enabling earlier identification, and greater public awareness encouraging individuals to seek medical advice. Progress in medical technology, alongside a deeper comprehension of cancer and its associated complications, is leading to a higher frequency of cancer cachexia diagnoses and reported cases. Medical practitioners are becoming more proficient at recognizing cachexia symptoms, which aids in commencing interventions and treatments sooner. For example, data from December 2023 by the Australian Bureau of Statistics, an Australian government body for national statistics, indicated that approximately 1.8% of Australia’s population, equivalent to 456,200 people, had cancer in 2022. Additionally, in May 2024, the National Cancer Institute, a U.S. federal government agency, projected that in 2024, around 2,001,140 new cancer diagnoses would occur in the U.S., with an anticipated 611,720 fatalities due to the illness. Globally, 2022 saw nearly 20 million new cancer occurrences and 9.7 million deaths linked to cancer. Projections suggest that by 2040, the annual count of new cancer cases will climb to 29.9 million, and cancer-related deaths will reach 15.3 million. Consequently, the rising incidence of cancer is a key factor propelling the expansion of the cancer cachexia market.

What Are The Major Segments Identified In The Cancer Cachexia Market?

The cancer cachexiamarket covered in this report is segmented –

1) By Therapeutics: Progestogens; Corticosteroids; Combination Therapies; Other Therapeutics

2) By Mechanism Of Action: Appetite Stimulators; Weight Loss Stabilizers; Other Mechanisms Of Actions

3) By Distribution Channel: Hospital Stores; Retail Pharmacy Stores; Online Pharmacies

Subsegments:

1) By Progestogens: Megestrol Acetate; Medroxyprogesterone Acetate; Hydroxyprogesterone Caproate

2) By Corticosteroids: Dexamethasone; Prednisolone; Methylprednisolone

3) By Combination Therapies: Progestogens + Corticosteroids; Progestogens + Anabolic Agents; Corticosteroids + Anabolic Agents

4) By Other Therapeutics: Anabolic Agents; Appetite Stimulants; Anti-inflammatory Drugs; Nutritional Supplements

What Trends Are Expected To Drive The Cancer Cachexia Market?

Leading companies in the cancer cachexia market are actively developing innovative medications, such as monoclonal antibodies for cachexia, to provide a targeted treatment for cancer cachexia, aiming to enhance body weight, muscle mass, and overall quality of life for affected individuals. A monoclonal antibody for cachexia works by targeting and inhibiting the factors that cause muscle and weight loss. For instance, in September 2024, Pfizer Inc., a US-based pharmaceutical company, announced the positive results from its Phase 2 study of Ponsegromab, a monoclonal antibody designed to target GDF-15, in patients with cancer cachexia. The study showcased a significant increase in body weight and improvements in muscle mass, appetite, and physical activity, with the 400 mg dose demonstrating the most robust outcomes. Based on these promising findings, Pfizer intends to initiate registration-enabling studies in 2025 to further evaluate Ponsegromab’s potential for treating cancer cachexia.

Which Key Players Are Driving Competition In The Cancer Cachexia Market?

Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Cancer Cachexia Market?

North America was the largest region in the cancer cachexia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Cancer Cachexia Market Report:

https://www.thebusinessresearchcompany.com/customise?id=15527&type=smp

Browse Through More Reports Similar to the Global Cancer Cachexia Market 2025, By The Business Research Company

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Breast Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Bone Cancer Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bone-cancer-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795